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Abstract.  GH4CI cells, a clonal strain of rat pituitary 
tumor cells, have high-affinity, functional receptors 
for the inhibitory hypothalamic peptide somatostatin 
(SRIF) and for epidermal growth factor (EGF). In this 
study we have examined the events that follow the 
initial binding of SRIF to its specific plasma mem- 
brane receptors in GH4C1 cells and have compared 
the processing of receptor-bound SRIF with that of 
EGF. When cells were incubated with [125I-Tyr~]SRIF 
at temperatures ranging from 4 to 37"C, >80% of the 
specifically bound peptide was removed by extraction 
with 0.2 M acetic acid, 0.5 M NaC1, pH 2.5. In con- 
trast, the subeellular distribution of receptor-bound 
12SI-EGF was temperature dependent. Whereas >95% 
of specifically bound ~2SI-EGF was removed by acid 
treatment after a 4"C binding incubation, <10% was 
removed when the binding reaction was performed at 
22 or 37"C. In pulse-chase experiments, receptor- 
bound ~2SI-EGF was transferred from an acid-sensitive 
to an acid-resistant compartment with a half-time of 2 
min at 37"C.  In contrast, the small amount of [~2sI- 
Tyrl]SRIF that was resistant to acid treatment did not 
increase during a 2-h chase incubation at 37"C. Chro- 
matographic analysis of the radioactivity released 
from cells during dissociation incubations at 37"C 
showed that >90% of prebound ~25I-EGF was released 
as ~2sI-tyrosine, whereas prebound [125I-Tyrl]SRIF  was 
released as a mixture of intact peptide (55%) and 1251- 
tyrosine (45%). Neither chloroquine (0.1  mM), am- 
monium chloride (20 mM), nor leupeptin (0.1  mg/ml) 
increased the amount of [125I-Tyr~]SRIF bound to 
cells at 37"C. Furthermore, chloroquine and leupeptin 
did not alter the rate of dissociation or degradation of 
prebound [12SI-Tyrl]SRIF.  In contrast, these inhibitors 
increased the amount of cell-associated ~2SI-EGF dur- 
ing 37"C binding incubations and decreased the subse- 
quent rate of release of 12sI-tyrosine. 
The results presented indicate that, as in other cell 
types, EGF underwent rapid receptor-mediated endo- 
cytosis in GH4CI cells and was subsequently degraded 
in lysosomes. In contrast, SRIF remained at the cell 
surface for several hours although it elicits its biologi- 
cal effects within minutes. Furthermore, a constant 
fraction of the receptor-bound [ 125  i_Tyr I  ]  SRIF was de- 
graded at the cell surface before dissociation. There- 
fore, after initial binding of [12SI-Tyrl]SRIF  and 1251- 
EGF to their specific membrane receptors, these pep- 
tides are processed very differently in GH4C~ cells. 
S 
OMATOSTATIN (SRIF) t is a  14 amino acid peptide that 
inhibits  secretion  by a large variety of pituitary,  pan- 
creatic, and gastrointestinal  target cells (28). The best- 
documented physiological function for SRIF is in the control 
of growth  hormone  secretion  by the  pituitary  gland  (28). 
GH4Cj cells, a clonal strain  of rat pituitary  tumor cells that 
synthesize and secrete both growth hormone and prolactin, 
provide  a  homogeneous  population of pituitary  target cells 
for studies of SRIF action (33, 40). These cells have specific, 
high-affinity membrane receptors for SRIF that mediate the 
inhibitory  effects of the peptide  on hormone secretion (32, 
33,  35). Inhibition  of secretagogue-stimulated  hormone re- 
lease by SRIF results  from  its  inhibition  of secretagogue- 
Abbreviations used in this paper: EGF, epidermal growth factor; F10-1h, Ham's 
Fl0  medium supplemented with  5  mg/ml lactalbumin  hydrolysate; SRIF, 
somatostatin; TLCK, Na-p-tosyl-L-lysine  chloromethyl ketone;  TPCK,  L-l- 
tosylamide 2-phenylethyl chloromethyl ketone. 
stimulated  adenylate  cyclase activity  (19) and  cyclic AMP 
production  (9,  10). In  addition,  SRIF inhibition  of basal 
hormone secretion  may result from a reduction  in intracel- 
lular  calcium  levels (10,  20,  3 l).  However,  although  SRIF 
receptors have been characterized in GH4C, cells, as well as 
in other cell types, little  is known about the processing of 
receptor-bound  SRIF after  the initial  binding  event at the 
plasma membrane. 
All peptide ligands examined  to date have been shown to 
interact  first with  membrane  receptors  on the cell surface. 
Thereafter many peptides are rapidly internalized by receptor- 
mediated  endocytosis  and  subsequently  degraded  in  lyso- 
somes  (1,  14,  23,  25). Therefore,  the  importance  of this 
internalization  process  in  eliciting  a  specific biological  re- 
sponse  and  in  regulating  target  cell sensitivity  to  peptide 
hormones and growth  factors is of general interest.  In the 
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follow the surface binding of [t2SI-TyP]SRIF in GH4CI cells. 
Because [t25I-TyP]SRIF appeared to be degraded by an unu- 
sual, nonlysosomal mechanism, we examined the processing 
of receptor-bound  ~2SI-epidermal growth  factor in  parallel 
experiments. We have previously shown that in GI-hCl cells 
epidermal growth factor (EGF) stimulates prolactin release 
and  synthesis,  inhibits  growth  hormone  production,  and, 
unlike its mitogenic effect in most other target ceils, reduces 
the rate of  cell proliferation (34). In this report we demonstrate 
that, as in other cell types (1,  14, 23, 25), ~2SI-EGF  is initially 
bound to surface receptors at 37"C and subsequently under- 
goes receptor-mediated endoeytosis and lysosomal degrada- 
tion. In contrast, under the same conditions, [~2~I-Tyf]SRIF 
is not internalized, and lysosomal proteases do not play a role 
in receptor-mediated [~25I-Tyr~]SRIF  degradation. A prelimi- 
nary report of some of these results has been presented (27). 
Materials and Methods 
Materials 
Materials were obtained  from the following Sources: synthetic  SRIF, [Tyrq- 
SRIF, thyrotropin-releasing  hormone, and bombesin from Bachem, Torrance, 
CA: EGF from ICN Biomedicals, Inc., Cambridge, MA; insulin, chlortxluine, 
leupeptin, tyrosine, L- l-tosylamide 2-phenylethyl chloromethyl ketone (TPCK), 
Nc~-p-tosyl-L-lysine  chloromethyl ketone (TLCK), iodoacetamide, phenylmeth- 
ylsulfonyI fluoride, baci~racin, soybean trypsin inhibitor,  puromycin,  a2-mac- 
roglobulin, activated charcoal, T70 dextram and N-2-hydroxyethylpiperazine- 
N'-2-ethanesulfonic  acid (Hepes) from Sigma Chemical  Co., St. Louis, MO; 
chloromercuribenzoate  from Aldrich Chemical  Co.,  Milwaukee, WI; chlora- 
mine T from Eastman  Kodak Co., Rochester,  NY; [fructose-l-~H(N)]sucrose 
( 10.8 Ci/mmol) and 2-deoxy-[ 1,2)H]glucose (37 Ci/mmol) from New England 
Nuclear,  Boston,  MA;  Na~ZSl (17 Ci/mg) and lactalbumin  hydrolysate from 
I.C.N. Nutritional  Biochemicals, Cleveland, OH: Sep-Pak Cts cartridges from 
Waters Associates, Milford, MA; Ham's FI0 culture  medium and sera from 
Gibco, Grand Island, NY; and culture  plates from Falcon Labware, Oxnard, 
CA. Phosphoramidon was the kind gift of Dr. A. Goldberg, Harvard  Medical 
School, Boston, MA. 
Cell Culture 
The properties  of the GH~C~ clonal  rat pituitary  tumor cell strain  and the 
method of its culture have been described previously (32, 33, 40). Experiments 
were performed using 35-mm dishes inoculated at a density of  2-3 x  l0  s cells/ 
dish from a single donor cell suspension and grown under identical conditions 
in 5% CO2/95% air at 37"C. The culture  medium was replaced every 3--4 d, 
and experiments were conducted  1.5-2 wk after plating. 
Radioiodination  of Peptides and Tyrosine 
[t2~l-Tyrt]SRIF was prepared  by chloramine  T iodination  as described previ- 
ously (32). The reaction  mixture  was purified  on a  Sephadex G-25 column 
eluted  with 0.1% bovine  serum albumin (BSA) in 0.087 M acetic acid. This 
chromatographic  procedure  separates  uniodinated  from radiolabeled  peptide 
and yields monoiodo[Tyrt]SRIF  with a specific activity of ~2,200 Ci/mmol. 
'~I-EGF was also prepared by chloramine T iodination and was purified by 
chromatography  on a  Sephadex  G-50  column eluled  with  0.05 M  NaPO4, 
0.075 M NaC|, 0.1% BSA, pH 7.5 (4). The minimum specific activity of ~sI- 
EGF was caicuiated assuming  complete recovery of  peptide and varied between 
1,200 and 2,000 Ci/mmol. 
Tyrosine  was  radioiodinated  by  the  chloramine  T  method as described 
previously (42). The minimum specific activity of the ~2*l-tyrosine  was calcu- 
lated to be 1.3 Ci/mmol. 
Measurement  of Peptide Binding to Cells 
Binding studies at 37"C were performed in Ham's FI0 medium supplemented 
with 5 mg/ml lactalbumin  hydrolysate (F10-1h)_ Experiments conducted at 22 
and 4"C were performed  in Fl0-1h lacking sodium  bicarbonate  and buffered 
with  20  mM  Hepes  at  pH  7.4  (Hepes-Fl0-1h).  The binding  of both  [~251- 
Tyr  t]SRIF and t251-EGF to GH4Ct cells were determined as described previously 
(32, 42). In brief, cells were equilibrated  to the temperature  of the  binding 
reaction in 1.0 ml of  the approi~riate medium, and then [~2~I-Tyr~]SRIF  or ~xst- 
EGF was added to a final concentration  of ~ t00,000 cpm/ml. The cells were 
incubated either at 37"C in a CO2-air incubator or at the indicated temperature 
in air. At the end of the binding incubation  cells were rapidly rinsed with 4"C 
saline and dissolved in 0.7 ml of I N NaOH. Cell-associated radioactivity was 
determined  in a Beckman 8000 Gamma counter (Beckman Instruments Inc., 
Palo Alto,  CA) at a counting  efficiency of 60%. The binding  of peptide  to 
specific, saturable receptors (specific binding) was calculated as the difference 
between  the  amount  of radiolabeled  peptide  bound  in  the  absence  (total 
binding) and presence (nonspecific binding) of excess unlabeled pepide. Non- 
specific [tzSI-Tyrt]SRIF and t251-EGF binding were measured  in the presence 
of 100 nM SRIF and  10 nM EGF, respectively, and composed  25% of total 
[mI-TyP]SRIF binding and 5% of total  ~2SI-EGF  binding. Values for specific 
binding are reported in all experiments unless otherwise specified. The standard 
error for specific binding was calculated by taking the square root of the sum 
of  the ~uares of the standard  errors for total and nonspeclfic binding. 
Measurement of 2-Deoxy-[1,2-3H]-Glucose 
and [Fructose-  l-3  H (N)]Sucrose Uptake 
I)eoxyglucose and sucrose uptake were measured  under the same incubation 
conditions  as peptide  binding.  After equilibration  at 37"C, cells were incu- 
bated with 3 uCi/ml of 2-deoxy-[I,2-3H]-glucose or 5 ~,Ci/ml of [fructose-l- 
~H(N)]sucrose for 60 min. The cells were subsequently rinsed rapidly with cold 
saline,  incubated  for an additional  10  min at  37*(:' to allow surface-bound 
deoxyglucose or sucrose to dissociate,  and then dissolved in 0.8  ml  of 1% 
Nonidet P-40. The cell-associated radioactivity was measured in 14 ml Aquasol 
with a Beckman LS7000 scintilation counter at a counting efficiency of 30%. 
Extraction of Cell-associated Radioactivity 
with Acid~Salt 
The  procedure  of Haigler  et  al.  (15) was  used  to  determine  the  cellular 
distribution  of specifically bound peptides. After the appropriate  incubations 
with radiolabeled peptide, cells were washed with cold saline and treated with 
1.0 ml of 4*C 0.2 M acetic acid, 0.5 M NaCI, pH 2.5 (acid/salt). After 3-5 min 
at 4"C, the extract was collected, the cells were rinsed with an additional  1 ml 
of acid/salt  solution,  and the two extracts  were combined.  Cells were then 
dissolved in 0.8 ml of 1 N NaOH. The radioactivity in both the acid/salt extract 
and the base solubilized cell residue was measured. All values were corrected 
to represent specific binding as described above. 
Measurement oft 251-  Tyrt]SRIF 
Binding to Membranes 
GH4C~ cell membranes were prepared by the procedure of Koch and Schon- 
brunn (19). Freshly thawed cell membranes were washed twice and resuspended 
in cold Tris buffer (50 mM Tris-HCl, 2 mM MgCI2, 2 mM EDTA, pH 7.6) at 
a protein  concentration  of ~1  mg/ml. The membranes were Teflon on glass 
homogenized at 4"C, and an equal volume of cold 50 mM Tris-HC1, 12 mM 
MgCI2, 2 mM EDTA, 2% BSA, 4 U/ml bacitracin,  pH 7.6, was added. The 
binding  reaction  was carried out in  1 ml of this buffer containing  ~150  vg 
membrane protein  and  100,000 cpm [~25I-TyP]SR1F. After 90 min at 37"C, 
the membranes were diluted with 3 vol 50 mM Tris-HCl, 7 mM MgCI2, 2 mM 
EDTA, 2 U/ml bacitracin,  pH 7.6 (binding buffer) containing  1% BSA and 
collected by centrifuging at 40,000 g for 10 min at 4"C. The supernatants  were 
removed, and the amount of radioactivity in the membrane pellet was deter- 
mined. Specific [J251-Tyr~]SRIF  binding was calculated as described for experi- 
ments with intact cells and represented 50-70% of total membrane binding. 
For  experiments  examining  the  dissociation  of membrane-bound [12:~I- 
TyP]SRIF,  the membranes were washed twice by centrifugation  at  10,000 g 
for 25 min at 4*(7 and then were incubated at 37"C in binding buffer containing 
0.05% BSA for the indicated period. At the end of this dissociation incubation 
the membranes were centrifuged at 40,000 g for 10 rain at 4"C, and the amount 
of radioactivity in the supernatant  and in the pellet was determined. 
Analysis of Radiolabeled Peptide Degradation 
Degradation  of ~2~I-EGF was assessed by  chromatography  on  Bio-Gel  P-2 
columns eluted with 0.05 M NaPO4, 0.075 M NaCI, 0.1% BSA, pH 7.5. ~251- 
EGF and ~251-tyrosine standards were run under the same conditions as exper- 
imental samples and eluted as single peaks. 
Degradation of [~25I-Tyrl]SRIF  was determined  using a modification of the 
method  of Bohlen et al.  (3). Samples were applied to Sep-Fak C~8  reversed 
phase cartridges prewashed with  10 ml methanol  and  10 ml water. NaJ251 was 
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5-ml  aliquots  of  0.1% trifluoroacetic  acid  in  25%  methanol,  and  [~2Sl- 
TyrqSRIF was eluted with two 5-ml aliquots of 0.1% trifluoroacetic acid in 
80% methanol.  Recovery of radioactivity from columns was >90%. 
The radioactive materials eluted from Sep-Pak C~s cartridges were further 
analyzed by high pressure liquid chromatography  to determine  whether they 
co-chromatographed with intact [~2SI-Tyr~]SRIF  or ~25I-tyrosine.  Samples eluted 
from the Sep-pak cartridges were evaporated to dryness on a Savant SpeedVac 
Concentrator  (savant Instruments, Inc., Hicksville, NY), redissolved in 0.1% 
trifluoroacetic acid, and applied to a Supelco Supelcosil LC-18 reversed-phase 
column (25 x 4.6 mm; Supelco, Inc., Bellefonte, PA). The column was eluted 
at a flow rate of I ml/min with a 45-min linear gradient of0.1% trifluoroacetic 
acid  to  0.1% trifluoroacetic  acid  in  80%  acetonitrile/20%  water.  [~25I- 
TyrqSRIF and ~25I-tyrosine standards were carried through the same protocol 
as experimental samples and eluted as single peaks. 
Measurement of[  1251-  Tyrt]SRIF Binding 
to Cytosolic Proteins 
The procedure of Reyl et al. (29, 30) was adapted for the detection of cytosolic 
[~251-TyrqSRIF binding proteins. GH4C~ cells were homogenized in 250 mM 
sucrose, 0.1  mg/ml soybean trypsin inhibitor,  10 mM Tris-HCl, pH 7.4. The 
cell homogenate was centrifuged at 100,000 g for 60 min at 4"C to remove all 
particulate  material.  Aliquots of the supernatant (0.25-0.6  mg protein)  were 
incubated  with  [~2~I-Tyr~]SRIF  (50,000  cpm) for  15  min at  22"C in a total 
volume of 0.5 ml. One ml of cold 0.25% charcoal, 0.025% T70 dextran, 0.5% 
BSA in  50  mM Tris-HCI, pH 7.4, was then  added,  and the  suspension was 
centrifuged at 2,500 g for  10  min at 4"C. This charcoal/dextran  adsorption 
procedure  removes  99%  of unbound  [~251-Tyr~]SRIF from  solution.  The 
amount of [~251-TyrqSRIF  bound to cytosolic proteins was determined  as the 
radioactivity remaining in the supernatant  after eharcoal/dextran  precipitation. 
As in all other binding experiments, both total and nonspecific binding were 
determined. 
Measurement of Cell Number and Protein 
Cell number was determined  as described by Schonbrunn et al. (34). Experi- 
ments were performed at a cell density of 1.5-2 x  10  ~ cells/35 mm dish. Cell 
protein was measured by the Pcterson modification (26) of the Lowry method 
using bovine albumin as a standard. 
Results 
Cellular Distribution  of  Receptor-bound Peptides 
Both morphological and biochemical studies have shown that 
fibroblasts internalize EGF by receptor-mediated endocytosis 
within minutes of receptor occupancy at physiologic temper- 
atures (1, 4,  14,  15, 23, 25).  To determine whether receptor- 
bound  SRIF was processed by a  similar pathway, we have 
used an acid extraction protocol originally developed by Haig- 
ler et  al.  for the  rapid  quantitation  of surface bound  and 
internalized  ~25I-EGF (15).  We  have  previously  used  this 
protocol to demonstrate that in GH4C~ cells, as in fibroblasts, 
receptor-bound EGF is transformed from an acid-extractable 
to an acid-resistant state within  10  min at  37"C  (42).  The 
experiment in Table I was carried out to determine the cellular 
distribution  of [J25I-TyrqSRIF bound  at different tempera- 
tures. 
GH4C~ cells were incubated with [~z~I-Tyr']SRIF at various 
temperatures and then treated with cold acid/salt as described 
in Materials and Methods (Table I). Unexpectedly, 86 __. 4% 
of the specifically bound [I~I-TyrqSRIF was acid extractable 
regardless of the temperature of the binding incubation.  In 
contrast,  the  distribution  of receptor-bound  ~:~I-EGF after 
similar binding incubations was markedly temperature de- 
pendent: the fraction of specifically bound '25I-EGF that was 
dissociated by acid after 2-h binding incubations at either 4 
or 37"C were 97 and 6%, respectively. 
To evaluate the extent of cellular leakage caused by acid 
Table I. Effect of  Binding Temperature on the Distribution of 
[125  I_ Tyr I]SRIF 
Specific binding 
Binding  A/S 
incubation  Total  A/S resistant  resistant 
cpm*  cprn*  % 
4"C 5 h  2,529 ___ 738  200 ___ 156  8 
22"C 3 h  10,510 -  654  1,437 _ 52  14 
37"C 1 h  6,712 + 580  1,341 +  156  20 
GH4C~ cells were incubated  with  [~25I-Tyr~]SRIF  (102,000 cpm/ml, 35  pM) 
under the conditions  shown.  The amount of specifically bound peptide was 
then determined  before (total) and after acid/salt  (A/S resistant) treatment  of 
the cells with 0.2 M acetic acid/0.5  M NaCl, pH 2.5, for 2-3 min at 4"C. 
* Mean _+ SEM of triplicate determinations. 
treatment,  we  measured  the  effect  of the  acid  extraction 
procedure on cell-associated 2-deoxy-[1,2-3H]-glucose. This 
glucose analogue is phosphorylated intracellularly and pro- 
vides a  useful marker for cytoplasmic constituents.  After a 
60-min binding incubation at 370C, exposure of cells to cold 
0.2 M  acetic acid/0.5  M  NaCl, pH 2.5,  for 3 min removed 
>80% of specifically bound [~25I-Tyr~]SRIF. However, in the 
same experiment, < 10 % of  cell-associated 2-deoxyglucose was 
removed by acid extraction (data not shown). Furthermore, 
extraction periods of 30 s to  15  rnin gave identical results. 
Therefore, treatment of GH4C~ cells  with  an acid  solution 
dissociates  most  of  the  specifically  bound  ['25I- 
Tyr  I]SRIF without causing significant leakage of cytoplasmic 
contents. 
The results in Table I indicated that if receptor-mediated 
internalization of [~25I-Tyf]SRIF occurred, its rate was much 
slower than that for ~25I-EGF  (42). To examine this difference 
further,  we  determined  the  cellular  distribution  of bound 
peptides after different periods of binding at 37°C  (Fig.  l). 
After 2 min at 370C, 80% of the specifically bound '25I-EGF 
was removed by acid treatment (Fig.  1, inset). However, the 
fraction of specifically bound  12SI-EGF that was resistant to 
acid extraction increased rapidly thereafter, and by 60 min 
<10% of the specifically bound radioactivity could be released 
(Fig.  l, top). In contrast, 82 _+  1% of the specifically bound 
[J2SI-Tyr~]SRIF was removed by acid treatment at all time 
points  examined  (Fig.  l,  bottom). The  acid-resistant  ['251- 
Tyr~]SRIF binding could not be accounted for by bulk pino- 
cytosis of the binding medium. Measurement of [fructose- l- 
3H(N)]sucrose uptake showed the rate of bulk pinocytosis at 
37°C to be 1.1 + 0.1 (n = 2) nl/min per l06 cells. This rate of 
pinocytosis could account for the internalization of <20 cpm 
of [ ~25I-Tyr~]SRIF  during the 60-min binding incubation. 
The low steady state level of intracellular [~25I-Tyf]SRIF 
could result from ligand internalization being followed rapidly 
by  degradation  and  extrusion  of radiolabeled  degradation 
products. If this were the case, radioactivity would not accu- 
mulate intracellularly. Therefore, to examine directly the fate 
of surface-bound [~25I-TyrqSRIF and ~25I-EGF,  we carried out 
pulse-chase experiments in which the redistribution of recep- 
tor-bound peptides between acid-sensitive and resistant com- 
partments was monitored (Fig.  2).  The binding of ~zSI-EGF 
was carried out at 4"C so that this peptide would remain at 
the cell surface. However, since the amount of[ ~25I-Tyrq  SRIF 
bound to cells at 4"C was substantially less than that bound 
at higher temperatures, and the fraction of the bound radio- 
activity that  was  acid  extractable  was  independent  of the 
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Figure  1.  Distribution  of receptor-bound  peptides  after  different 
periods of binding at 37"C. GH4C~ cells were incubated at 37"C with 
either '25I-EGF (99,500 cpm/ml, 47 pM) or ['25I-TyP]SRIF (155,000 
cpm/ml, 53 pM). At the indicated times, cells were treated with 0.2 
M  acetic  acid/0.5  M  NaCI,  pH  2.5,  at  4"C,  and  the  amount  of 
specifically bound peptide removed by (O) and resistant to (Q) acid/ 
salt extraction was determined as described in Materials and Methods. 
Error bars represent the standard  error of triplicate determinations 
for ['2~[-TyrtISRIF and duplicate determinations for '~I-EGF. 
temperature of the binding incubation (Table I), [~25I-TyP]- 
SRIF binding was done at 37"C. After the binding incubations, 
37"C  medium without  radiolabeled peptides was added  to 
cells,  and  the  distribution  of receptor-bound  peptides was 
determined as a function of time (Fig. 2). 
Receptor-bound ~25I-EGF  was rapidly transformed from an 
acid-extractable to an acid-resistant compartment at 37*(2 (t,/~ 
-- 2  min).  In contrast, the fraction of receptor-bound [~25I- 
Tyr~]SRIF present in an acid-resistant state remained at or 
below its  initial  value  of 20%  throughout  a  90-min  chase 
incubation at 37"C. Although the amount of acid-extractable 
[~zSI-Tyr~]SRIF decreased during this period (t,/~ =  60 rain), 
this decrease was due to dissociation of the peptide into the 
medium, not to its translocation into an acid-resistant com- 
partment. The addition of a saturating concentration of SRIF 
(100 nM) to the chase medium did not alter the distribution 
of receptor-bound ['25I-Tyr~]SRIF (data not shown), demon- 
strating that the level of receptor occupancy did not influence 
the processing of receptor-bound ligand. 
In summary, surface bound [~2~I-Tyr~]SRIF was not redis- 
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Figure 2. Redistribution of surface-bound peptides at 37*(2. GH,C~ 
cells were incubated with either ~2SI-EGF  (171,000 cpm/ml, 80 pM) 
for 5 h at 4"C or with ['251-TyP]SRIF  (157,000 cpm/ml, 54 pM) for 
45 rain at 37"C. After the binding reaction, the cells were rapidly 
rinsed with 4"C saline, and fresh 37"C F10-1h was added (t = 0). At 
the indicated times the amount of  specifically  bound peptide removed 
by (O) and resistant to (Q) acid/salt (A/S) extraction was determined 
as described in Materials and Methods. Specific  binding at t = 0 was 
29,660 _+ 690 cpm for  12~I-EGF and  9,752 __. 202  cpm for [~2~I- 
TyP]SRIF. Error bars represent the standard error of duplicate deter- 
minations. 
tributed in pulse-chase experiments. In addition, the fraction 
of receptor-bound [t:5I-TyP]SRIF that was acid-resistant was 
always small (<20%) and did not vary with either the tem- 
perature  or the  duration  of the  binding  incubation.  These 
data argue strongly for the conclusion that the  l0 to 20% of 
[125I-Tyrl]SRIF binding that was acid resistant results from 
incomplete dissociation under the conditions of  the extraction 
procedure. Therefore, our results indicate that in GHaCI cells, 
receptor-bound ~2~I-EGF  is rapidly internalized whereas [t25I- 
Tyrl]SRIF is not. 
In addition  to EGF,  three  other peptides also appear to 
undergo rapid receptor-mediated endocytosis in GH4Ct cells: 
thyrotropin releasing hormone (17),  bombesin (42),  and in- 
sulin (7). However, the addition of saturating concentrations 
of these  peptides to  the  chase  medium  did  not  alter  the 
fraction  of receptor-bound  ['25I-TyrqSRIF that  was disso- 
ciated by acid after either 30- or 60-rain incubations at 37"C 
(data not shown). Thus, simulataneous, rapid endocytosis of 
heterologous peptides do not affect the cellular distribution 
of receptor-bound [125I-TyP]SRIF. 
Degradation of  Receptor-bound Peptides 
The lack of internalization of receptor-bound [12~I-Tyrt]SRIF 
881  Presky and Schonbrunn Bound Somatostatin  and EGF Table II. Degradation of  Receptor-bound [~25I-Tyr~]SRIF 
% Total t~I 
Sample  ~2~1  Fraction I  Fraction II  Fraction III 
cpm* 
Standards 
[~251-Tyr~]SRIF  43,040 + 210  2  2  97 
zzSI-Tyrosine  30,530 +  180  5  90  5 
Binding medium  44,000 _ 210  1  5  95 
Cell extract 
Specific  7,490 + 363  0  1  99 
Dissociation medium 
Specific  4,700 + 350  2  46  53 
Nonspecific  2,190 _ 270  0  11  89 
GH4C, cells  were incubated  at 37°C with ['251-TyrqSRIF  ( 150,000 cpm/ml, 51 pM) in the presence  or absence  of 100 nM SRIF. After  60 min,  the binding  medium 
was removed, and the cells  were rapidly rinsed in 4°C saline  before being  divided into two groups. One group was immediately  extracted with I ml 0.2 M acetic 
acid/0.5 M NaCl, pH 2.5, for 3 rain at 4*C (Cell extract). The other group was incubated  for an additional  60 min at 37°C in 1.0 ml fresh Fl0-1h medium  to allow 
dissociation of cell-associated radioactivity  (dissociation  medium). Samples and standards were analyzed  by chromatography on reverse-phase minicolumns  as 
described in Materials  and Methods. Fractions  I, II, and lI! represent  the radioactivity  eluted  with  0.1% trifluoroacetic  acid, in 0, 25, and 80% methanol,  respectively. 
Recovery of radioactivity  from the columns  was >95% for all samples. Errors were _+ 2% for triplicate  determinations. 
* Mean _+ SEM of duplicate  determinations. 
suggested that the binding of this peptide to its plasma mem- 
brane receptor  should  be  truly reversible,  resulting in the 
release of intact ['2SI-Tyr~]SRIF  into the medium. Two chro- 
matographic procedures were  used to  examine directly the 
nature of the [125i.Tyr,]SRiF_derived material that dissociated 
from  cells.  Stepwise elution of reverse-phase  minicolumns 
was  used to  achieve a  rapid and convenient separation of 
intact [~25I-Tyrt]SRIF from its probable degradation product, 
'25I-tyrosine (Table II). High-performance liquid chromatog- 
raphy was performed to  provide better resolution between 
intact ['zSI-TyrqSRIF and possible intermediate peptide deg- 
radation products (Fig. 3). 
After incubation of [~25I-Tyr']SRIF  with GH4C, cells for 60 
min at  37°C,  the  specifically bound radioactivity extracted 
from cells with acid/salt co-eluted with intact ['25I-Tyr~]SRIF 
both on minicolumns  (Table II) and high-performance liquid 
chromatography (Fig. 3 C). Therefore, ['25I-Tyr']SRIF  specif- 
ically bound at the surface of cells represents intact peptide. 
In contrast, the specifically bound radioactivity released into 
the medium during a subsequent 60-min incubation at 37°C 
chromatographed as ~50% intact peptide and 50%  ~25I-tyro- 
sine (Table II and Fig. 3, A and B). This degradation was not 
due to instability of the peptide in the medium since ['zsI- 
TyrqSRIF incubated in Fl0-1h for 60 min under the same 
conditions  remained 95% intact (Table II). Furthermore, 90% 
of the  nonspecifically bound [~zSI-Tyr']SRIF dissociated as 
intact peptide (Table II), indicating  that the degradation must 
be a receptor-mediated process. 
We next measured the rates of release of both intact [125I- 
Tyr']SRIF and ~25I-tyrosine from cells to determine whether 
radioactivity was  released primarily as  intact peptide early 
and as degradation products later. The results shown in Fig. 
4  demonstrate  that  the  rates  of  release  of  intact  [125I- 
TyrJ]SRIF and ~25I-tyrosine from cellular receptors were in- 
distinguishable: receptor-bound [tESI-Tyr~]SRIF was released 
as  -50%  intact peptide and -50%  ~25I-tyrosine at all time 
points examined. In contrast, when cells were incubated with 
~25I-EGF for 60 min at 37°C, the radioactivity released during 
a subsequent 60-min incubation  at 37°C chromatographed as 
>90%  ~25I-tyrosine (data not shown). These results are con- 
sistent with the fate of receptor-bound '25I-EGF in other cell 
types:  rapid  internalization of the  peptide  is  followed  by 
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Figure 3. Identification of the degradation products of receptor-bound 
[J25I-Tyri]SRIF by HPLC.  GH4C, cells were incubated  with  [~25I- 
TyrqSRIF for 60 min at 37"C. After the binding  incubation,  the cells 
were rapidly rinsed in 4"C saline, incubated for 5 min at 37"C to 
allow >75%  of the nonspecifically bound [~25I-Tyr~]SRIF  to disso- 
ciate, and then divided into two groups. One group was immediately 
extracted with 0.2 M acetic acid/0.5 M NaCI (cell extract). The other 
group was incubated for an additional 60 rain at 37"C in fresh medium 
to allow dissociation of cell-associated  radioactivity (release medium). 
Samples were first  purified  by  stepwise elution on  reverse-phase 
minicolumns  and then analyzed by reverse-phase high-performance 
liquid chromatography as described in Materials and Methods. A and 
B show the elution profiles of the release media fractions eluted from 
reverse-phase minicolumns  with 25 % methanol/0.1% trifluoroacetic 
acid (fraction II, 7,100 cpm) and 80% methanol/0.1% trifluoroacetic 
acid (fraction Ill, 7,000 cpm), respectively. C represents the elution 
profile of the cell extract fraction eluted from Sep-Pak minicolumns 
with 80%  methanol/0.1%  trifluoroacetic acid (fraction III, 24,000 
cpm). The retention times of [~25I-Tyr']S  ""~' and ~2~I-tyrosine  stand- 
ards are shown by arrows. Recovery for all samples was >85%. 
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cells (1,  14, 23, 25). 
The results presented demonstrate that ['2~I-Tyr']SRIF  is 
degraded upon dissociation from cellular receptors without 
prior internalization. Therefore, in  marked contrast to the 
lysosomal degradation previously reported for z2~I-EGF and 
other internalized peptide ligands,  receptor-mediated degra- 
dation of [~25I-Tyr~]SRIF is more likely to occur at the plasma 
membrane than in lysosomes. 
Effect of  Lysosomal lnhibitors on Peptide 
Binding and Processing 
To evaluate further the role of lysosomal enzymes in  the 
degradation of receptor-bound peptides in GH~C~ cells we 
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Figure  4.  Time  course  for  the  release of [t2SI-Tyrl]SRIF and  J2~I- 
tyrosine from GH4C~  ceils. GH4C~  cells were incubated with  [J25I- 
Tyr~]SRIF (136,000 cpm/ml, 46 pM) for 60 min at 37"C. After the 
binding incubation, the cells were rinsed with 4°C saline (t =  0) and 
then  incubated at  37°C  for the  indicated  times.  The  radioactivity 
accumulated  in  the  medium  was analyzed by  chromatography  on 
reverse-phase minicolumns as described in Materials and Methods. 
The amount of radioactivity eluted with 25% methanol/0.1% triflu- 
oroacetic acid (O) (co-chromatographing with ~25I-tyrosine)  and with 
80%  methanol/0.1%  trifluoroacetic acid (O)  (co-chromatographing 
with intact [tzSI-Tyr~]SR1F)  are shown. All values have been corrected 
for nonspecific binding.  Specific binding at  t  =  0  was 7,382  _+  20 
cpm. Error bars represent the standard error of duplicate determina- 
tions. 
determined the effects  of the  lysosomal inhibitors chloro- 
quine, ammonium chloride, and leupeptin on the binding of 
'25I-EGF and ['25I-Tyr~]SRIF and the subsequent release of 
their  degradation  products.  Chloroquine  and  ammonium 
chloride inhibit lysosomal proteolysis  by reducing the trans- 
membrane pH gradient of lysosomes. Leupeptin is a specific 
inhibitor of thiol proteases, including cathepsin B. The results 
in Fig. 5 and Table III show that chloroquine and leupeptin 
increased the amount of cell-associated  '25I-EGF during pro- 
longed 37°C binding incubations. However, neither inhibitor 
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Figure 5.  Effect of leupeptin  and chloroquine on  peptide binding. 
GH4C~  cells were preincubated at 37°C for 60 min either in Fl0-1h 
alone (O) or with 0.1  mg/ml leupeptin (©) or 0.1  mM chloroquine 
(A). J25I-EGF  ( 165,000 cpm/ml, 77 pM) or [ t2~I-Tyr']SRIF (140,000 
cpm/ml, 48 pM) were then added, and the incubations were contin- 
ued at 37"C. At the times shown, the amount of specifically bound 
peptides was  determined  as  described  in  Materials  and  Methods. 
Error bars represent the standard error of duplicate determinations. 
Table 111. Effect of  Leupeptin and Chloroquine on [~25I-TyrJ]SRIF Processing 
Chase incubation  ['Z~l-TyrqSRIF bound  % A/S 
Time  Treatment  Total  A/S resistant  resistant 
% Intact 
peptide 
rain 
0 
30 
60 
cpm*  cpm* 
Control  10,677 +  463  1,675 +  98  16  -- 
Leupeptin  9,346 +  92  1,472 +  8  16  -- 
Chloroquine  5,215 _+  131  952 _  43  18  -- 
Control  6,150 +  151  1,144 __+ 44  9  -- 
Leupeptin  5,537 __+ 28  1,031  ___ 19  9  -- 
Chloroquine  3,491  _  76  800 ___ 27  23  -- 
Control  3,110 _+ 301  602 _+ 34  9  64 
Leupeptin  3,385 ___ 212  777 _  85  23  65 
Chloroquine  1,725 ___ 146  505 -4- 59  29  68 
GH~C~ cells were preincubated at 37"C with 0.1 mg/ml leupeptin for 60 min or 0.1 mM chloroquine for 30 min. [t2~I-Tyr']SRIF (150,000 cpm/ml, 51  pM) was 
then added, and the incubations were continued for 60 min at 37"C. The distribution of specifically bound ['2~I-Tyr']SRIF between acid/salt (A/S)-resistant  and 
-sensitive compartments was determined either immediately after the binding incubation (t = 0) or after an additional  30- or 60-rain  incubation in fresh 37"C 
medium containing the appropriate inhibitor. The nature of  the radioactivity released during the 60-min chase incubation at 37"C was determined by chromatography 
of the medium on reverse-phase minicolumns as described in Materials and Methods. The percent intact peptide was calculated from the ratio of the amount of 
radioactivity  eluted from the columns with 80% methanol, 0.1% trifluoroacetic acid to the total radioactivity eluted. All values have been corrected for nonspecific 
binding. 
* Mean ___ SEM of duplicate or triplicate determinations. 
883  Presky and Schonbrunn Bound Somatostatin  and EGF increased the amount of ['25I-Tyr~]SRIF bound to cells during 
a 4 to 6 h incubation at 37"C. In fact, chloroquine caused a 
marked decrease in  [12SI-TyrI]SRIF binding at all times ex- 
amined. However, the effect of chloroquine to decrease ['25I- 
TyP]SRIF binding is probably not a  result of its lysosomo- 
tropic action. When  lysosomal function was inhibited with 
20 mM ammonium chloride, the amount of ~25I-EGF bound 
to cells during 4 h at 37"C was increased to 210% of untreated 
controls. In the same experiment ['25I-TyP  ]SRIF binding was 
unaffected by the ammonium chloride. 
The results in Fig. 6 show the effect of chloroquine on the 
rate of release of radioactivity after the binding of I25I-EGF 
and [t2~I-TyP]SRIF to cells.  The half-time for the release of 
'25I-tyrosine  derived from receptor-bound '25I-EGF was in- 
creased from 45  min in control cells to  150 min in chloro- 
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Figure 6.  Effect of chloroquine  on  the  release of cell-associated 
radioactivity. GI-LC, cells were preincubated  for 30  min at  37"C 
either in Fl0-1h alone (0) or in the presence of 0.1 mM chloroquine 
(O). Subsequently, either '2SI-EGF  (125,000 cpm/ml, 59 pM) or ['251- 
Tyrl]SRIF (103,000 cpm/ml, 35 pM) was added, and the incubations 
were continued  for  90  rain  for  '25I-EGF and  60  rain  for  ['25I- 
Tyr']SRIF. After the binding incubation, the cells were rapidly rinsed 
with 4°C saline, and the dissociation reaction was initiated at t = 0 
by the addition of  fresh 370C F 10-1h medium in the continued absence 
or presence ofchloroquine. The amount of  specifically  bound peptide 
was determined at the indicated times as described in Materials and 
Methods. Specific binding before the initiation of the dissociation 
reactions was 7,131 _+ 67 cpm (0) and 3,949 +_ 325 clam (O) for ['25I- 
Tyr']SR1F and  13,810 _+ 210 (0) and  15,540 _+ 70 (O) cpm for 125I- 
EGF. Each point represents the mean of  duplicate determinations. B, 
bound. 
quine-treated cells. In contrast, the rate of release of radioac- 
tivity after [~25I-Tyr']SRIF  binding was not significantly al- 
tered by chloroquine treatment: the half-times were 49 and 
41  min in the absence and presence of chloroquine, respec- 
tively. Similarly, 0.1  mg/ml leupeptin decreased the rate of 
release of ~25I-EGF  derived radioactivity whereas the dissocia- 
tion rate for [t25I-Tyrt]SRIF derived material was unchanged 
(t,h = 48 rain). 
We next determined the effects of chloroquine and leupep- 
tin on the cellular distribution and subsequent degradation of 
specifically bound  [~2~I-Tyr']SRIF (Table III). Neither chlo- 
roquine nor leupeptin changed the ratio of acid-extractable to 
acid-resistant ['25I-TyP]SRIF after a 60-min binding incuba- 
tion at 37"C. Furthermore, neither agent altered the cellular 
distribution  of [t25I-Tyr~]SRIF after a  30- or 60-min chase 
incubation  at  37"C.  Finally,  neither  inhibitor  changed  the 
ratio of intact [~25I-TyP]SRIF to ~25I-tyrosine  that was released 
by the cells. 
The observation that chloroquine and leupeptin increased 
the steady state levels of'zsI-EGF accumulated in GI-LC, cells 
and decreased the subsequent rate of release of '25I-tyrosine 
indicates  that,  as  in  fibroblasts,  internalized  '25I-EGF was 
degraded in lysosomes. In contrast, these inhibitors did not 
increase  the  steady  state  accumulation  of  cellular  ['251- 
Tyr']SRIF, nor did they alter the subcellular distribution or 
degradation of this peptide. Combined with the apparent lack 
of internalization  of [~25I-Tyr']SRIF,  these  results  provide 
compelling evidence for the conclusion that the degradation 
of specifically bound ['25I-TyP]SRIF does not occur in lyso- 
somes. 
Degradation  of [125l-TyrllSRIF by 
GH4CI Cell Membranes 
To  assay  directly  for  membrane  proteases  that  might  be 
responsible  for  the  degradation  of  receptor-bound  ['25I- 
Tyr']SRIF, we examined the nature of the radioactivity re- 
leased  after  binding  [t25I-TyP]SRIF to  GH4C~ cell  mem- 
branes. In contrast to intact cells, 85-90% of the specifically 
bound radioactivity released from membranes during disso- 
ciation incubations of 2-4 h chromatographed as intact ['25I- 
TyP]SRIF (Table IV). In addition, the amount of degradation 
was not  affected by  100  nM  SRIF.  Nonspecifically bound 
peptide dissociated  as  82%  intact  [~25I-TyP]SRIF,  showing 
the same small amount of degradation as specifically bound 
pcptide (data not shown). The observation that specific pro- 
teolysis of receptor-bound peptide did not occur in isolated 
Table IV. Degradation of  [~2SI-Tyr']SRIF Bound to Membranes 
% Intact 
Dissociation incubation  t251 bound  ~2Sl dissociated  [t25I-Tyr=]SRIF* 
cpm*  cpm* 
0  21,449 +  750  --  -- 
2 h  15,791  _+ 421  7,378 +  50  90 
4 h  11,630 +  742  10,576 _  360  87 
4 h  +  100 nM SRIF  9,695 +  849  10,791  _+ 343  85 
GI-LC~ membranes (150 pg/ml) were incubated with [mI-TyP]SRIF  (342,000 cpm/ml, 120 pM) for 90 min at 37°C in the absence or presence of 100 nM SRIF as 
described in Materials and Methods. The membranes were then collected by centrifugation,  washed twice, and resuspended in 37°C binding buffer containing 
0.05% BSA with or without SRIF. Alter incubating at 37°C with shaking for the indicated amount of time the membranes were centrifuged at 40,000 g for 10 min 
at 4°C. The nature of the dissociated material present in the supernatants  was analyzed on Sep-Pak C~8 reverse-phase minieolumns,  and the binding of [nSI-Tyr~]- 
SRIF to the membranes were determined as described in Materials and Methods. 
* Mean +- SEM of triplicate determinations. 
Percent dissociated ~2sI. 
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for  such  degradation  or  that  the  proteases  involved  were 
inactivated during the process of membrane preparation. 
Effect of  Protease Inhibitors on 
[12~  l_ Tyrt  ]SRl  F Degradation 
To  characterize  further  the  enzyme(s)  responsible  for  the 
degradation  of receptor-bound  [12SI-Tyrl]SRIF  in  cells  we 
examined the effects of several protease inhibitors and unla- 
beled SRIF on peptide degradation. The presence of  saturating 
concentrations of SRIF (100 nM and 0.1  raM) in the disso- 
ciation  medium had only a  slight effect on  [12~l-Tyrl]SRIF 
degradation (Table V). Therefore this degradation was either 
catalyzed by a  low-affinity enzyme or else  receptor-bound 
peptide was not released into the medium before degradation. 
Bacitracin, a noncompetitive inhibitor of papain and subtili- 
sin; phenylmethylsulfonyl fluoride, a general irreversible in- 
hibitor of serine proteases; TLCK, an irreversible inhibitor of 
trypsin-like enzymes; a2-macroglobulin, which binds and in- 
activates a  wide  variety of proteases;  and  puromycin,  an 
inhibitor  of certain  aminopeptidases,  had  the  same  small 
effect on receptor-mediated degradation as did 0.1 mM SRIF. 
However, TPCK, an inhibitor of chymotrypsin-like enzymes; 
the two sulfhydryl reagents iodoacetamide and chloromercu- 
ribenzoate; and phosphoramidon, which inhibits metalloen- 
doproteases, substantially inhibited receptor-mediated degra- 
dation of [~25I-TyP]SRIF (Table V). 
Table V. Effect of  Peptidase Inhibitors on Degradation of 
[12s  L Tyr I]SRIF Bound to Cells 
% Intact 
~251  [tZSl.Tyrt  ]. 
Treatment  released  SRIF 
cpm* 
Exp.  1 (B~-o =  8,596 -4- 246) 
Control  3,947 __. 358  54 
SRIF  (100 nM)  4,362  ___ 104  60 
(0.1 mM)  4,293  ___ 321  65 
Bacitracin  (0.5 mM)  5,190  __+ 501  65 
PMSF  (0.1 mM)  5,562_ 165  63 
TLCK  (0.1 mM)  6,357  ___ 484  67 
TPCK  (0.1 mM)  7,789  _.+ 105  87 
lodoacetamide  (1.0 mM)  6,834  ___ 286  72 
Chloromercu-  (0.1 mM)  6,810  + 224  80 
ribenzoate 
Exp. 2 (Bt..o =  8,064 -e 48) 
Control  2,686 _+  130  54 
az-Macroglobulin  (50 ug/ml)  2,217 _  44  64 
Exp. 3 (Bt-o =  9,866 ±  128) 
Control  2,613 _+ 124  52 
Purornycin  (0.1  mM)  2,034 _+ ! 42  56 
Phosphoramidon  (0.1  mM)  1,703 __ 45  70 
GH4C~ cells were incubated with [~2~I-Tyrt]SRIF ( 115,000 cpm/ml, 39 pM) for 
60 rain at 37"C. After the binding reaction, the cells were rinsed with 4"C saline 
and fresh 37"C Fl0-1h containing the indicated compounds was added (t = 0). 
After 60 rain at 37"C, the radioactivity released into the medium was measured 
and  then analyzed 'by chromatography on  reverse-phase minicolumns (see 
Materials and Methods). The percent intact peptide was calculated from the 
ratio of the amount of ~2~I eluted from the columns with 80% methanol, 0.1% 
trifluoroacetic acid (fraction lIl) to the total  radioactivity eluted. All values 
have been corrected for nonspecific binding. For experiment 3, inhibitors were 
added 30 min before the initiation of the binding incubation. PMSF, phenyl- 
methylsulfonyl fluoride.  B, bound. 
* Mean _+ SEM of triplicate determinations. 
Table VI. Binding of  [~2sI  -Tyrl]SRIF to GH4C~ cytosol 
t251 in 
~2~I in precipitate  supernatant 
cpm*  cpm* 
No cytosol  43,438 _+ 220  662 _+ 32 
Cytosol  41,403 _+ 223  2,697 + 74 
Cytosol +  100 nM SRIF  41,418 -  211  2,682 __. 15 
GH4C~ cell cytosol (255 ttg protein/0.5 ml) was incubated with [12~I-Tyr~]SRIF 
• (44,100  cpm/0.5 ml, 30 pM) in the absence (total binding) or presence (non- 
specific binding) of 100 nM SRIF. After 15 min at 22"C, the amount of [~I- 
Tyrt]SRIF  remaining free  in  solution was determined by charcoal-dextran 
adsorption as described in Materials and Methods. Both the amount of lt2Sl  - 
Tyd]SRIF precipitated by charcoal and the amount remaining in solution were 
measured. 
* Mean _+ SEM of quadruplicate determinations. 
Binding of[  a  2SI-Tyrl]SRIF to Cytosolic Proteins 
Recent reports have suggested that an intracellular cytosolic 
receptor for SRIF accounts for most of the [~25I-Tyrl]SRIF 
binding in gastric mucosal and pancreatic cells (29, 30). These 
cytosolic receptors are  reported  to  mediate  stimulation  of 
soluble phosphoprotein phosphatases by SRIF (29). However, 
our results indicate that receptor-bound SRIF is not internal- 
ized in GI-hC1 cells. Therefore, following procedures similar 
to those described by Reyl and Lewin (29),  we have tried to 
identify saturable binding sites for [~25I-Tyd]SRIF  in GH4C1 
cell cytosol. The results in Table VI show that the binding of 
[125I-Tyd]SRIF to cytosolic proteins was not decreased by 100 
nM unlabeled SRIF and therefore must represent binding to 
a low-affinity site.  The lack of high-affinity binding sites for 
SRIF in GH4C~ cell cytosol combined with the observation 
that receptor-bound SRIF remains at the cell surface while it 
inhibits hormone release indicate that the biological actions 
of SRIF in GH4CI cells are initiated at the plasma membrane. 
Discussion 
In this study we have shown that receptor-bound SRIF and 
EGF are processed very differently in GH4CI  cells.  Whereas 
~25I-EGF underwent rapid receptor-mediated internalization 
and was subsequently degraded in lysosomes, [125I-Tyrl]SRIF 
remained bound at the cell surface and  was degraded in a 
nonlysosomal compartment. The absence of [125I-Tyf]SRIF 
internalization is not due to a general defect in GH4C~ cells: 
~zSI-EGF is internalized with the same rapid  kinetics as in 
other cell types, and both [125I-Tyrl]SRIF and SRIF are bio- 
logically active in GH4CI cells under the conditions of the 
binding incubation (32,  35).  In fact, SRIF elicits a maximal 
inhibitory effect on  hormone  secretion  within  5  rain  (32; 
Koch, B. D., and A. Schonbrunn, unpublished observations). 
The rapid biological action of SRIF combined with the lack 
of rapid  internalization  indicate  that  SRIF  must  elicit  its 
biological effects at the plasma membrane. 
To examine the cellular processing of receptor-bound pep- 
tides in GH4CI cells we have used an acid extraction protocol 
first introduced by Haigler et al.  for distinguishing intracel- 
lular and extracellular ~zSI-EGF  (15). This indirect biochemi- 
cal method for quantitating the extent of internalization of 
receptor-bound  peptides  has  produced  results  in  excellent 
agreement  with  morphological  studies  using  appropriately 
labeled peptide analogs (1,  14,  23,  25).  In fact, pH-induced 
dissociation of peptides from their receptors is a physiological 
885  Presky and Schonbrunn Bound Somatostatin and EGF mechanism for intracellular segregation of ligands  and their 
receptors within acidic, prelysosomal vesicles (8, 41). 
The kinetics of receptor-mediated internalization, as mea- 
sured by translocation of  bound peptides from an acid-extract- 
able to an acid-resistant compartment, were markedly differ- 
ent for [~zSI-Tyr~]SRIF  and ~25I-EGF in GHaCI cells. ~25I-EGF 
was internalized rapidly (t,/2 =  2 min), as previously observed 
in a variety of cell types (1, 4,  14-16, 23, 25, 42). In contrast, 
under  identical conditions,  receptor-bound [~2~I-Tyr~]SRIF 
was not transformed into an acid-resistant state at either low 
(<10%) or high (>95%) levels of receptor occupancy. Fur- 
thermore, the addition of saturating concentrations of heter- 
ologous peptides, which themselves undergo rapid internal- 
ization, did not alter the distribution  of bound  [~2~I-Tyrl]  - 
SRIF.  Therefore  receptor-bound  [I~I-Tyr~]SRIF  must  be 
processed independently of EGF, thyrotropin releasing hor- 
mone, bombesin, and insulin in GH~C~ cells. Similarly, Cie- 
chanover et  al.  have  found  that  insulin,  transferrin,  and 
asialoglycoproteins are processed independently after binding 
to their respective receptors in hepatoma cells (6). 
Since receptor-bound [125I-Tyr~]SRIF appeared not to be 
rapidly internalized, we expected that its binding would be 
fully reversible and that dissociated radioactivity would con- 
sist entirely of the intact peptide. Although all the surface- 
bound material was  intact [~2~I-Tyrl]SRIF, radioactivity re- 
leased from cells was composed of an approximately equal 
mixture of intact peptide and its degradation product,  12~I- 
tyrosine. Since such degradation has been assumed to reflect 
receptor-mediated endocytosis and lysosomal degradation of 
other hormones (22),  we compared the effects of lysosomal 
protease inhibitors on the processing and degradation of [t2sI- 
Tyr~]SRIF and  ~2~I-EGF. Lysosomotropic agents have been 
shown to increase the intracellular accumulation of peptides 
that are degraded in lysosomes and therefore should enhance 
the ability to detect peptides usually present intracellulady 
only at low steady state concentrations (l,  14,  23,  25).  Al- 
though chloroquine, NH~C1, and leupeptin elicited the  ex- 
pected increase in  ~I-EGF accumulation  in  GH4C~ cells, 
none of these inhibitors increased the cellular accumulation 
of total or acid-resistant [I2SI-Tyr~]SRIF. In fact, chloroquine 
caused a 50% decrease in [~2~I-Tyr~]SRIF  binding at all times. 
This effect of chloroquine was probably due to nonspecific 
membrane perturbation rather than to its lysomotropic action 
because ammonium chloride, which inhibits lysosomal func- 
tion by a similar mechanism, did not decrease [~25I-Tyr~]SRIF 
binding. Furthermore, neither chloroquine nor leupeptin al- 
tered the rate of  degradation or dissociation of  receptor-bound 
[~2~I-Tyrl]SRIF under conditions in which they inhibited the 
degradation of ~2~I-EGF. These results indicated that receptor- 
mediated  degradation  of [125I-Tyrl]SRIF did  not  occur in 
lysosomes. 
Although unusual, nonlysosomal degradation of  a receptor- 
bound peptide has been observed previously. In rat adipocytes 
receptor-bound insulin was degraded by a  mechanism that 
markedly  resembles  the  process  of SRIF  degradation  in 
GH,C~ cells (13, 38). Whereas >95% of the specifically bound 
ligand was intact ~25I-insulin, the radioactive material disso- 
ciated from receptors consisted of an  approximately equal 
mixture of intact ~sI-insulin and iodotyrosine (13). Degrada- 
tion was specific for receptor-bound peptide since only intact 
t~sI-insulin was released from nonspecific binding sites. Fur- 
thermore, the fraction of receptor-bound l/5I-insulin that was 
degraded did not vary with receptor occupancies between l 
and  90%,  demonstrating that  ~25I-insulin degradation  was 
proportional to receptor occupancy (13). Leupeptin did not 
decrease receptor-mediated ~25I-insulin degradation, nor did 
it increase the accumulation of cellular 125I-insulin (38). Al- 
though chloroquine did increase cell-associated  tESI-insulin 
during binding incubations,  it had only a  small  effect on 
receptor-mediated  degradation, and two other lysosomotropic 
agents,  methylamine and  NH4C1, did not  increase insulin 
binding (38). Since lysosomotropic agents did not uniformly 
decrease the degradation of ~25I-insulin or increase its intra- 
cellular accumulation,  the  major degradation  pathway for 
receptor-bound t2sI-insulin in adipocytes was proposed to be 
nonlysosomal (38). 
In GH4C1 cells degradation of receptor-bound [IZ~I-Tyr~]- 
SRIF was unaffected by the presence of  excess unlabeled SRIF 
in the dissociation medium. This lack of protection is con- 
sistent  with  the  hypothesis that  the  degrading enzyme or 
enzymes have low affinity (Kin >  10  -4 M) for [~zSI-Tyr~]SRIF. 
However, the  observation that  [~25I-Tyr~]SRIF degradation 
occurred  at  the  very  low  [~zsI-Tyrl]SRIF  concentrations 
(~10 -13  M)  present  in  the  medium  when  [~zSI-Tyr~]SRIF 
dissociates from its receptor makes this explanation unlikely. 
Alternatively, the receptor itself may mediate the degradation 
of  [~25I-Tyr~]SRIF or  directly  transfer  the  bound  [125I- 
Tyr~]SRIF to the degrading enzyme(s). The latter mechanisms 
have also been postulated for the adipocyte insulin receptor 
but remain to be proven (1 1, 38). 
Membrane proteases have been hypothesized to catalyze 
the  nonlysosomal degradation of insulin in  rat adipocytes; 
however a  protease that selectively  degrades only receptor- 
bound J25I-insulin has not been identified (1 1, 38). Similarly, 
we could not identify specific degradation of receptor-bound 
[1251-Tyr~]SRIF in  GH4C~ membranes.  Although  receptor- 
mediated degradation of ~25I-insulin in adipocytes and [~2~I- 
Tyrl]SRIF in GH4Ct cells appear to occur by similar mecha- 
nisms, there are some significant differences between the two 
systems.  In adipocytes, intact insulin was released somewhat 
more rapidly than iodotyrosine ( 13, 24). In fact, the increasing 
degradation of receptor-bound insulin  observed with  time 
correlated with the conversion of the insulin receptor from a 
rapidly to a slowly dissociating state (24).  In contrast, after 
[~25I-Tyr~]SRIF  binding to GH4C1 cells, intact [J2SI-Tyr~]SRIF 
and ~25I-tyrosine  were released at the same rate. Furthermore, 
the dissociation of both [~25I-Tyr~]SRIF  and ~25I-tyrosine  fol- 
lowed simple first-order kinetics, and the same dissociation 
rate constant was observed whether equilibrium binding had 
been achieved or the dissociation reaction was initiated pre- 
equilibrium (32). These results indicate that the affinity state 
of the  SRIF receptor does not change during the  binding 
reaction and that both intact and degraded peptide dissociate 
from a single form of  the receptor. The fact that intermediate 
degradation products were not found in the dissociation me- 
dium  suggested  that  an  aminopeptidase  cleaved the  NH2- 
terminal  125I-tyrosine residue from [~25I-Tyr~]SRIF. Such an 
activity has been reported in  GH cells  (12).  Alternatively, 
intermediate degradation products may be too unstable to 
accumulate to detectable levels. 
To characterize further the proteases that degrade receptor- 
bound [~25I-Tyf]SRIF,  we examined the ability of different 
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ously, chloroquine and leupeptin did not inhibit [~2SI-Tyr~]- 
SRIF degradation. Bacitracin, phenylmethylsulfonyl fluoride, 
TLCK,  a2-macroglobulin, and puromycin had only a small 
effect.  Only phosphoramidon, TPCK and the sulfhydryl pro- 
tease  inhibitors  iodoacetamide  and  chloromercuribenzoate 
produced substantial inhibition of [~25I-Tyr~]SRIF degrada- 
tion. Interestingly, sulthydryl protease inhibitors also reduced 
the nonlysosomal degradation of receptor-bound ~25I-insulin 
in rat adipocytes (38). It must be kept in mind, however, that 
these inhibitors can have multiple targets and are quite toxic 
to cells. Therefore, the inhibitors may be eliciting their effects 
indirectly rather than by specific inactivation of degradative 
enzymes. 
The  importance  of ligand-receptor internalization in  the 
mechanism of action of peptide hormones and growth factors 
remains unresolved because an agent that selectively inhibits 
the process of receptor-mediated  internalization without se- 
rious side effects has not been discovered. Since anti-receptor 
antibodies have been shown to mimic the effects  of EGF (36) 
and insulin (18), internalization of these ligands was suggested 
to be unnecessary for their biological activity. However, since 
anti-receptor  antibodies  lead  to  the  internalization  of the 
receptors for both insulin (5) and EGF (37), receptor inter- 
nalization may be required.  We have demonstrated that ['25I- 
TyrZ]SRIF is biologically active under conditions where it is 
not internalized (35). In addition, we have found that SRIF 
receptor number is increased rather than decreased by SRIF 
pretreatment  (manuscript  in  preparation).  The  absence  of 
internalization of either SRIF or its receptor under conditions 
where SRIF inhibits hormone secretion indicates that these 
processes are not required  for SRIF action in GH4C~ cells. 
Reyl  and  Lewin  have  reported  that  most  of the  SRIF 
binding sites in rat pancreatic and gastric  mucosal cells are 
cytosolic  and  have  proposed  that these  binding sites  may 
mediate the biological actions of SRIF by stimulating soluble 
phosphoprotein phosphatase  activity  (29,  30).  We  did  not 
detect any high-affinity binding of [~25I-Tyr~]SRIF to cytosolic 
proteins prepared from GH4CI ceils. The absence of receptor- 
mediated  uptake  of  [J25I-Tyr']SRIF  suggests  that,  even  if 
cytosolic receptors were present, they would not be accessible 
to SRIF. Therefore, these results  further support the conclu- 
sion that the actions of SRIF are  mediated  directly by the 
plasma membrane receptor in GH4C, cells.  In fact, the SRIF 
receptor present in  membranes  prepared  from  GH4C~ cells 
inhibits adenylate cyclase activity (19), and this effect clearly 
initiates at least some of the biological actions of SRIF (10, 
33).  However, the fact that the SRIF receptor is coupled to 
adenylate cyclase does not explain its unique form of process- 
ing:  other receptors that either stimulate (e.g., ~-adrenergic 
receptors)  or  inhibit (e.g.,  enkephalin  receptors)  adenylate 
cyclase have been shown to mediate rapid endocytosis of their 
respective ligands (2, 21, 39). 
In summary, we have shown that the processing events that 
follow  the  initial  binding  of [~25I-Tyr']SRIF  to  its  plasma 
membrane  receptor differ  markedly  from those that follow 
binding of all other peptide ligands that have been studied in 
GH4C, cells.  Receptor-bound ['25I-Tyr~]SRIF remains at the 
cell surface while it elicits its biological effects  and is partially 
degraded by membrane proteases,  apparently simultaneously 
with dissociation. The importance of SRIF degradation in its 
mechanism  of action  and  the  consequences of the  lack  of 
rapid internalization  for receptor regulation and desensitiza- 
tion present interesting questions for study. 
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